Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.64 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.64 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.64 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.64 |
| ▸ | PTGER2 | P43116 | 14/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3831628 | 0.85 | KCNA5 (0.64) | KCNA5KCNE1KCNQ1KCND3PTGER2 | |
| SCHEMBL3816026 | 0.84 | KCNA5 (0.60) | KCNA5KCNE1KCNQ1KCND3PTGER2 | |
| SCHEMBL1379727 | 0.83 | KCNE1 (0.70) | KCNA5KCNE1KCNQ1KCND3POLB | |
| SCHEMBL1377355 | 0.83 | KCNE1 (0.67) | KCNA5KCNE1KCNQ1KCND3POLB | |
| SCHEMBL3893634 | 0.83 | KCNA5 (0.64) | KCNA5KCNE1KCNQ1KCND3POLB | |
| SCHEMBL1379274 | 0.82 | KCNA5 (0.61) | KCNA5KCNE1KCNQ1KCND3POLB | |
| SCHEMBL15014670 | 0.82 | KCNA5 (0.66) | KCNA5KCNE1KCNQ1KCND3POLB | |
| SCHEMBL3886253 | 0.81 | KCNA5 (0.67) | KCNA5KCNE1KCNQ1KCND3POLB | |
| SCHEMBL3886811 | 0.80 | KCNA5 (0.74) | KCNA5KCNE1KCNQ1KCND3PTGER2 | |
| SCHEMBL3898299 | 0.80 | KCNE1 (0.63) | KCNA5KCNE1KCNQ1KCND3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776355-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-06-12 | — | — | EP | claimed |
| JP-4719744-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | claimed |
| US-20060030595-A1 | (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias | MERCK SHARP & DOHME LLC | 2006-02-09 | — | — | US | claimed |
| EP-1776355-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-1776355-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-06-12 | — | — | EP | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20060030595-A1 | (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias | MERCK SHARP & DOHME LLC | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030595-A1 | (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias | KCNN2, KCNJ2, KCNH2 | KCNA5 14/4885KCNE1 9/4885KCNQ1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.